Influence of ischemia before vein grafting on early hyperplasia of the graft and the dynamic changes of the intima after grafting

Journal of Cardiothoracic Surgery

QingKui Guo¹  ZhiQian Lu¹  MingJuan Sun²  RongJiang Zou¹ 

[1] Department of Cardiothoracic Surgery, Shanghai No6 People's Hospital, Shanghai JiaoTong University, 600 YiShan Road, Shanghai, 200233, China;Department of Biochemistry and molecular biology, Second Military Medical University, Shanghai, Peoples Republic of China

关键词: Endothelial cell;    Intimal hyperplasia;    Ischemia;    Vein graft;   

Others  :  1152848
DOI  :  10.1186/1749-8090-7-90

 received in 2012-02-03, accepted in 2012-09-20,  发布年份 2012

【 摘 要 】

Background

To investigate both the influence of ischemia before grafting on early hyperplasia of the vein grafts, and the dynamic changes of the intima after grafting in a rabbit model of vein graft disease.

Methods

We performed paired vein graft experiments under different ischemic conditions (15 vs. 60 min; 15 vs. 90 min) in the neck of the rabbits and compared the differences between the grafts. Clopidogrel, an anti-platelet agent, was administered before and after surgery. Twenty-eight days after the grafting procedure, the veins were evaluated microscopically. The dynamic changes of the intima after grafting were evaluated by scanning electron microscopy over time.

Results

The vein grafts subjected to 60- or 90-min ischemia exhibited no differences compared to those subjected to 15-min ischemia in terms of the mean thickness of the intimal, medial, and adventitial layers of the graft. Similarly, there was no difference in the Ki-67 labeling index (proliferation marker) between the vein grafts. Vein grafts with 15-min ischemia lost endothelial cells (ECs) but healed by 3 days post graft, whereas vein grafts with 90-min ischemia suffered serious EC loss, which was restored with new ECs during days 2 to 14 post graft.

Conclusions

Ninety-minute ischemia before vein grafting can cause serious EC loss, but does not increase early intimal hyperplasia when clopidogrel is administered. Protecting the vein from ischemia and reperfusion injury preserves ECs.

【 授权许可】

   
2012 Zou et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

【 参考文献 】

• [1]Bourassa MG: Fate of venous grafts: the past, the present, and the future. J Am Coll Cardiol 1991, 5:1081-1083.
• [2]Fitzgibbon GM, Kafka HP, Leach AJ, Keon WJ, Hooper GD, Burton JR: Coronary bypass graft fate and patient outcome: angiographic follow-up of 5065 grafts related to survival and reoperation in 1388 patients during 25 years. J Am Coll Cardiol 1996, 28:616-626.
• [3]Campeau L, Enjalbert M, Lespérance J, Bourassa MG, Kwiterovich P Jr, Wacholder S, Sniderman A: The relation risk factor to the development of atherosclerosis in saphenous vein bypass grafts and the progression of disease in the native circulation: a study 10 years after aortocoronary bypass surgery. N Engl J Med 1984, 311:1329-1332.
• [4]Motwani J, Topol E: Aortocoronary saphenous vein graft disease: pathogenesis, predisposition, and prevention. Circulation 1998, 97:916-931.
• [5]Thatte HS, Biswas KS, Najjar SF, Birjiniuk V, Crittenden MD, Michel T, Khuri SF: Multi-photon microscopic evaluation of saphenous vein endothelium and its preservation with a new solution, GALA. Ann Thorac Surg 2003, 75:1145-1152.
• [6]Sakaguchi T, Asai T, Belov D, Okada M, Pinsky DJ, Schmidt AM, Naka Y: Influence of ischemic injury on vein graft remodeling: role of cyclic adenosine monophosphate second messenger pathway in enhanced vein graft preservation. J Thorac Cardiovasc Surg 2005, 129:129-137.
• [7]Souza DSR, Johansson B, Bojö L, Karlsson R, Geijer H, Filbey D, Bodin L, Arbeus M, Dashwood MR: Harvesting the saphenous vein with surrounding tissue for CABG provides long-term patency comparable to the left internal thoracic artery: results of a randomised longitudinal trial. J Thorac Cardiovasc Surg 2006, 132:373-378.
• [8]Mangano DT, For the Multicenter Study of Perioperative Ischemia Research Group: Aspirin and mortality from coronary bypass surgery. N Engl J Med 2002, 347:1309-1317.
• [9]Eagle KA, Guyton RA, Davidoff R, Edwards FH, Ewy GA, Gardner TJ, Hart JC, Herrmann HC, Hillis LD, Hutter AM Jr, Lytle BW, Marlow RA, Nugent WC, Orszulak TA, Antman EM, Smith SC Jr, Alpert JS, Anderson JL, Faxon DP, Fuster V, Gibbons RJ, Gregoratos G, Halperin JL, Hiratzka LF, Hunt SA, Jacobs AK, Ornato JP: American College of Cardiology; American Heart Association Task Force on Practice Guidelines; American Society for Thoracic Surgery and the Society of Thoracic Surgeons. ACC/AHA 2004 guideline update for coronary artery bypass graft surgery: summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Update the 1999 Guidelines for Coronary Artery Bypass Graft Surgery). Circulation 1999, 110:1168-1176.
• [10]Shuhaiber JH, Evans AN, Massad MG, Geha AS: Mechanisms and future directions for prevention of vein graft failure in coronary bypass surgery. Eur J Cardiothorac Surg 2002, 22:387-396.
• [11]Cavallari N, Abebe W, Mingoli A, Sapienza P, Hunter WJ 3rd, Agrawal DK, Cavallaro A, Edwards JD: Short-term preservation of autogenous vein grafts: effectiveness of University of Wisconsin solution. Surgery 1997, 121:64-71.
• [12]Solberg S, Larsen T, Jørgensen L, Sørlie D: Cold-induced endothelial cell detachment in human saphenous vein grafts. J Cardiovasc Surg 1987, 28:571-575.
• [13]CAPRIE Steering Committee: A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996, 348:1329-1339.
• [14]Anderson HV, McNatt J, Clubb FJ, Herman M, Maffrand JP, DeClerck F, Ahn C, Buja LM, Willerson JT: Platelet Inhibition Reduces Cyclic Flow Variations and Neointimal Proliferation in Normal and Hypercholesterolemic-Atherosclerotic Canine Coronary Arteries. Circulation 2001, 104:2331-2337.
• [15]Ross R: Atherosclerosis—an inflammatory disease. N Engl J Med 1999, 340:115-126.
• [16]Graff J, Harder S, Wahl O, Scheuermann EH, Gossmann J: Anti-inflammatory effects of clopidogrel intake in renal transplant patients: effects on platelet-leukocyte interactions, platelet CD40 ligand expression, and proinflammatory biomarkers. Clin Pharmacol Ther 2005, 78:232-241.
• [17]Li M, Zhang Y, Ren H, Zhang Y, Zhu X: Effect of clopidogrel on the inflammatory progression of early atherosclerosis in rabbits model. Atherosclerosis 2007, 194:348-356.
• [18]Ishikawa M, Sasajima T, Kubo Y: Re-endothelialisation in autogenous vein Grafts. Eur J Vasc Endovasc Surg 1996, 11:105-111.
• [19]Ehsan A, Mann MJ, Dell'Acqua G, Tamura K, Braun-Dullaeus R, Dzau VJ: Endothelial Healing in Vein Grafts: Proliferative Burst Unimpaired by Genetic Therapy of Neointimal Disease. Circulation 2002, 105:1686-1692.
• [20]Barner HB, Fischer VW: Endothelial preservation in human saphenous veins harvested for coronary grafting. J Thorac Cardiovasc Surg 1990, 10:148-149.
• [21]Zhang L, Freedman NJ, Brian L, Peppel K: Graft-Extrinsic Cells Predominate in Vein Graft Arterialization. Arterioscler Thromb Vasc Biol 2004, 24:470-476.
• [22]Goldman S, Copeland J, Moritz T, Henderson W, Zadina K, Ovitt T, Kern KB, Sethi G, Sharma GV, Khuri S: Starting aspirin therapy after operation. Effects on early graft patency. Department of Veterans Affairs Cooperative Study Group. Circulation 1991, 84:520-552.
• [23]Gavaghan TP, Gebski V, Baron DW: Immediate postoperative aspirin improves vein graft patency early and late after coronary artery bypass graft surgery. A placebo-controlled, randomized study. Circulation 1991, 83:1526-1533.
• [24]Halkos ME, Cooper WA, Petersen R, Puskas JD, Lattouf OM, Craver JM, Guyton RA: Early administration of clopidogrel is safe after off-pump coronary artery bypass surgery. Ann Thorac Surg 2006, 81:815-819.
• [25]Chan V, Kulik A, Bourke ME, Ressler L, Mesana TG, Ruel M: Clopidogrel is safe early after on- and off-pump coronary artery bypass surgery. J Card Surg 2007, 22:493-497.